Home / Business and Economy / Applovin Surges as Allegations Debunked
Applovin Surges as Allegations Debunked
10 Feb
Summary
- Applovin stock increased after a publisher retracted claims of criminal ties.
- Oracle shares rose on increased tech spending despite AI concerns.
- Hims & Hers shares dropped due to a lawsuit over obesity drug knock-offs.
Applovin's stock experienced a significant surge on Monday, recovering from allegations of links to transnational crime syndicates. This rebound followed a retraction of explosive claims by a financial publisher, which had accused the company of facilitating illicit fund transfers.
Meanwhile, Oracle shares continued their upward trend, rallying as much as 12%. This recovery was bolstered by increased capital spending from major US technology firms on data centers and AI infrastructure, easing concerns surrounding the impact of artificial intelligence on the company's business.
In contrast, Hims & Hers Health saw its stock price decline. The company is facing a lawsuit from Novo Nordisk A/S, which alleges that Hims & Hers manufactured unapproved versions of its popular obesity medicines. This legal challenge emerged despite Hims & Hers discontinuing its own plans to release a copycat version of Novo Nordisk's Wegovy.
